Corporate debt recently passed the $1 trillion mark in a continuing sign of global financial displacement.Marketsread more
"Federal debt, which is already high by historical standards, is on an unsustainable course," CBO director Phillip Swagel said in the report.Politicsread more
Target CEO Brian Cornell still thinks the U.S. consumer is strong and spending. Target's latest quarterly results showed the big-box retailer is benefiting from that.Retailread more
"If you look at the market over the past week, stocks don't need any help. They are roaring ahead, without the Fed doing anything," says the longtime market strategist.Marketsread more
Stocks rose on Wednesday as strong quarterly results from retailers such as Target and Lowe's lifted investor sentiment.US Marketsread more
President Trump insists the economy is healthy and says the only thing holding U.S. growth back is the Federal Reserve.Marketsread more
Trading volumes this week are well below recent averages, and that means this comeback may be suspect.Marketsread more
Shares of Tesla slid Wednesday on news of Walmart's lawsuit.Technologyread more
The rule could defy a 2015 Flores Settlement Agreement court order that says families cannot be held in detention for more than 20 days.Politicsread more
A key indicator for the commercial real estate market is showing signs of weakness, and uncertainty in the economy over the trade war and interest rates may be to blame.Real Estateread more
Bank of America CEO Brian Moynihan is not worried about an economic slowdown, saying the U.S. consumer is still in a strong place.Banksread more
(Adds Bayer declining to comment, detail on board statement)
BERLIN, May 1 (Reuters) - The supervisory board of Bayer is planning an extraordinary meeting to discuss a crisis of confidence in its leadership after an investor rebuke at the German drugmaker's annual meeting, a magazine reported on Wednesday.
Citing an unnamed board member, Wirtschaftswoche magazine said the meeting would take place in the next two or three weeks: "We can't just carry on like this," the person said.
A Bayer spokesman declined to comment.
At Bayer's annual shareholder meeting on Friday a majority of investors cast a vote of disapproval of top management's actions.
On Saturday, the supervisory board said in a statement that it unanimously stands behind the company's management, adding that it would continue to examine the results of the AGM in the weeks ahead.
On Monday, three of Bayer's largest German investors said the drugmaker's management needed to stay at the helm to avoid further upheaval, despite their unease over a share price slump in the wake of the company's $63 billion takeover of Monsanto.
About 30 billion euros ($34 billion) have been wiped off Bayer's market value since August, when a U.S. jury found it liable because Monsanto had not warned of alleged cancer risks linked to its weedkiller Roundup. More than 13,000 plaintiffs are claiming damages.
Bayer is appealing or plans to appeal the Roundup verdicts and has pointed to global regulators' findings that the use of glyphosate, the active ingredient in the herbicide, is safe.
On Tuesday, the U.S. Environmental Protection Agency (EPA) said that glyphosate is not a carcinogen, contradicting decisions by U.S. juries that found it caused cancer in people.
($1 = 0.8904 euros) (Reporting by Emma Thomasson; editing by Jason Neely and Susan Fenton)